Pailin Bio disclosed its 2026 interim report. In the first half, it achieved operating revenue of 830 million yuan, down 15.88% year on year. Net profit attributable to shareholders of the listed company was 84.301 million yuan, down 64.25% year on year. Basic earnings per share were 0.09 yuan. The company also plans to distribute a cash dividend of 1.5 yuan per 10 shares, tax included. The company said the blood products industry has been affected by factors such as the expansion of centralized procurement, DRG and DIP reforms, medical insurance cost control, and key monitoring of rational drug use. Clinical prescription volumes have declined, and demand-side prosperity in the market has weakened, causing the gross margin of the blood products business to fall year on year. In addition, starting from January 1, 2026, blood products are no longer included in the 3 percent simplified VAT levy scope and are instead subject to the 13 percent general taxation method, which further lowered the reporting period's gross margin. The company expects product supply in the second half of 2026 to be more ample than in the first half, and the short-term impact of the VAT collection method change to diminish. Full-year performance is expected to show a trend of being lower in the first half and higher in the second half.
Pacific Shuanglin Bio pharmacy Co LtdNet profit fell 64.25% year on year due to lower demand and VAT change.
